(JAMA Neurology) The investigational anti-tau antibody bepranemab missed its primary cognitive endpoint in a phase II trial ...

Disclaimer: This article contains mentions of drug abuse. Reader discretion is advised. Barry Keoghan, who has been open ...

The Alzheimer's disease drug Kisunla will face major reimbursement challenges in the U.K. after the cost-effectiveness ...

After dosing with Cognition’s CT1812, study reports declines of 95% and higher in subgroup with below-median p-tau217.

Cassava then released the altered data in a press release and investor deck, which led the SEC to allege that the company and ...

New research reveals that lecanemab, an Alzheimer's drug previously hailed for slowing disease progression, may increase the ...

Semaglutide, the weight management drug sold as Ozempic and Wegovy, may reduce the risk of Alzheimer's disease by 40% to 70% ...

The Journal of the Alzheimer’s Association” — has linked the active ingredient in both of these drugs, semaglutide, to ...

In a small early trial using a transcranial magnetic stimulation procedure, scientists were able to target a key brain ...

Alzheimer’s disease patients prescribed fistfuls of daily drugs are at greater risk of harm, a new study warns.Patients ...